Search
forLearn
5 / 801 resultslearn valine
learn HT-B
learn glutamic acid
learn gentian
Research
5 / 1000+ results
research Efficacy of Compound GV-350 with Tricofer® Iron, Cystine and Biotin in the Management of Telogen Effluvium in Women with Iron Deficiency
GV-350 improves hair growth and quality of life in iron-deficient women without side effects.
research SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Entospletinib effectively prevents eye and skin GVHD in mice.
research MCMV Infection Lowers the Threshold for the Development of Clinical GvHD after Allogeneic Bone Marrow Transplantation.
CMV infection increases the risk of GvHD after bone marrow transplants.
research Graft-versus-host reaction. Cutaneous manifestations following bone marrow transplantation.
Skin changes help detect graft-versus-host reaction early after bone marrow transplants.
research Graft-versus-host disease
Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.
Community Join
5 / 1000+ resultscommunity Trump halted all federal funding for medical research in the US. Will this affect any current treatments in the pipeline?
Federal funding for medical research in the U.S. has been halted, potentially delaying new treatments. Hair loss treatments like finasteride and minoxidil are unlikely to be impacted as they are typically funded by private companies.
community A Short Recap on PP405 and AAD 2026
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
community Juicero is not an analogy for PP405. Stop bringing that up.
PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."
community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
community Is pp405 actually the cure ? Just how exciting is it ?
PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.